In the majority of clinical trials patients are randomised equally between treatment groups.
This approach maximises statistical power for a given total sample size.
The objectives of this paper were to determine if, when research costs between treatments differ, it is more economically efficient to randomise additional patients to the cheaper treatment, and how the optimum randomisation ratio can be estimated.
Estimation of the most economically efficient randomisation ratio for four hypothetical clinical trials using cost-effectiveness analysis.
When research costs differ between treatments, and there is no constraint on total sample size, it is always more cost-effective to randomise more patients to the cheaper treatment.
For example, a cost ration between the lesser and more expensive treatment of ten, results in a randomisation ratio of 3.2 : 1. Conclusions : Unequal randomisation ratios should be more widely used as this will achieve optimum statistical power for the lowest expenditure of research resources.
Mots-clés Pascal : Analyse coût efficacité, Sciences économiques, Médecine, Recherche scientifique, Médecin, Pratique professionnelle, Essai clinique, Chimiothérapie, Traitement, Théorie, Méthodologie
Mots-clés Pascal anglais : Cost efficiency analysis, Economics, Medicine, Scientific research, Physician, Professional practice, Clinical trial, Chemotherapy, Treatment, Theory, Methodology
Notice produite par :
ORS Auvergne - Observatoire Régional de la Santé d'Auvergne
Code Inist : 002B30A11. Création : 21/07/1998.